Beginning April 13, 2020, the Association of Public Health Laboratories (APHL) has conducted a weekly survey of up to 100 state, local and territorial public health laboratories (PHLs) to collect the status of current and projected capability and capacity of laboratories to test for SARS-CoV-2, the virus that causes the Coronavirus Disease (COVID-19). Data from this survey is used to inform HHS, FEMA, CDC and other federal partners to support public health laboratory supply and reagent needs.

**OVERALL TESTING CAPACITY**

Current testing and supply demands (n=86)

- **179,961**
  - Number of specimens tested during the previous week (Data from CDC)
- **85%**
  - PHLs able to meet their current testing demand
- **19%**
  - PHLs that will run out of reagents or supplies within a week

**SEROLOGY / ANTIBODY TESTING**

Status of serological testing implementation (n=99)

- **24%**
  - Currently perform serological testing
- **52%**
  - Intend to perform serological testing
- **24%**
  - Serological testing not planned yet

**HIGH THROUGHPUT TESTING PLATFORMS**

Status of high throughput testing platforms* in the laboratory (n=99)

- **61%**
  - Labs with at least one high throughput platform
- **39%**
  - Labs without a high throughput platform

**Number of high throughput platforms** per laboratory, of those with at least one (n=60)

- **57%**
  - 1 high throughput platform
- **23%**
  - 2 high throughput platforms
- **10%**
  - 3 high throughput platforms
- **5%**
  - 4 high throughput platforms
- **3%**
  - 5 high throughput platforms
- **2%**
  - 6 high throughput platforms

*Data based on survey-long compilation

* High throughput platforms are automated equipment that can test many specimens at a time while minimizing the hands-on time required by laboratory staff. High throughput platforms currently in use are Hologic Parter, Hologic Panther Fusion, Abbott m200 and the BD Max.